Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response

European Journal of Neurology

Volumn 19, Issue 6, 2012, Pages 899-904

  Rio J ^a   Tintore M ^a   Sastre Garriga, J ^a   Nos, C ^a   Castillo J ^a   Tur, C ^a   Comabella, M ^a   Montalban, X ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Glatiramer acetate; Interferon; Mitoxantrone; Multiple sclerosis; Natalizumab; Switch therapy; Treatment response

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB;

ADULT; ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; REMISSION; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS; PEPTIDES; RECURRENCE; TREATMENT FAILURE; YOUNG ADULT;

EID: 84860920485     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03648.x     Document Type: Article

References (25)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
2. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995. Neurology 2001; 57(12 Suppl. 5): S16-S24.
3. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998 Nov 7; 352:1498-1504.
4. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294.
5. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
6. Hartung HP, Gonsett R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind randomized multicenter trial. Lancet 2002; 360: 2018-2025.
7. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
8. Río J, Comabella M, Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol 2009; 5: 553-560.
9. Carra A, Onaha P, Luetic G, et al. Therapeutic outcome 3years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. Eur J Neurol 2008; 15: 386-393.
10. Caon C, Din M, Ching W, Tselis A, Lisak R, Khan O. Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2006; 13: 471-474.
11. Gajofatto A, Baccheti P, Grimes B, High A, Waubant E. Switching first-line disease modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. Mult Scler 2009; 15: 50-58.
12. Castillo-Trivino T, Mowry EM, Gajofatto A, et al. Switching multiple sclerosis patients with breakthrough disease to second line therapy. PLoS ONE 2011; 6: e16664.
13. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002; 59: 1496-1506.
14. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-1460.
15. Durelli L, Barbero P, Bergui M, et al. The OPTimization of Interferon for MS Study: 375 mug interferon beta-1b in suboptimal responders. J Neurol 2008; 255: 1315-1323.
16. The PRISMS Study Group. PRISMS-4: long-term efficacy of interferon-beta- 1a in relapsing MS. Neurology 2001; 56: 1628-1636.
17. Limmroth V, Malessa R, Zettl UK, et al. Quality assessment in multiple sclerosis therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. J Neurol 2007; 254: 67-77.
18. Río J, Nos C, Tintoré M, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006; 59: 344-352.
19. O'Rourke K, Walsh C, Antonelli G, Hutchinson M. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. Mult Scler 2007; 13: 336-342.
20. Healy BC, Glanz BI, Stankiewicz J, Buckle G, Weiner H, Chitnis T. A method for evaluating treatment switching criteria in multiple sclerosis. Mult Scler 2010; 16: 1483-1489.
21. O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009; 8: 889-897.
22. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008; 7: 903-914.
23. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW; Therapeutics Technology Assessment Subcommittee of the American Academy of Neurology. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010; 74: 1463-1470.
24. Oturai AB, Koch-Henriksen N, Petersen T, Jensen PE, Sellebjerg F, Sorensen PS. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 2009; 16: 420-423.
25. Putzki N, Yaldizli O, Mäurer M, et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol 2010; 17: 31-37.